BridgeBio Oncology Therapeutics, Inc. BBOT
2.20 USD -0.10 (-4.35%)
At closeNov 10, 2026, 4:52 PM EST
2.30 +0.10 +4.55%
After hours · Nov 10, 4:52 PM ET
2.19 Day range 2.34
1.98 52-week range 14.87
- YTD
- -82.43%
- 1 year
- -82.66%
News
benzinga.com BridgeBio Oncology Q3 EPS $(0.43) Beats $(0.69) Estimate BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.69) by 37.68 percent. This is a 58.25 percent increase over losses of…
globenewswire.com BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients BBO-11818 and BBO-10203 combination cohorts…
benzinga.com Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13 Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.- benzinga.com Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16 Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.
seekingalpha.com BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff BridgeBio Oncology Therapeutics is rated Speculative Buy, with a risk-adjusted valuation of $3.76 per share, implying 33% upside. BBOT's pipeline, led by BBO-11818, targets multiple KRAS mutations…
globenewswire.com BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway…
defenseworld.net BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Consensus Rating of “Moderate Buy” from Analysts BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) has earned an average rating of "Moderate Buy" from the ten analysts that are presently covering the firm, Marketbeat.com…
defenseworld.net Brokerages Set BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Price Target at $22.88 BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the stock,…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regular session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON)…
benzinga.com Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27 Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.
benzinga.com Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20 Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.
benzinga.com Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22 Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…- benzinga.com Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15 Stifel analyst Laura Prendergast maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $15.
- benzinga.com Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.
benzinga.com Bridgebio Announces New KRASG12C Data And Strategic Prioritization Of BBO-8520 In Combination With Checkpoint Inhibitor In 2L+ KRASG12C Inhibitor-Experienced NSCLC Patients And BBO-11818 And BBO-10203 In KRAS-Mutant Cancers BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly…
globenewswire.com BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway…
globenewswire.com BBOT to Participate in Upcoming Investor Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway…- benzinga.com JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25 JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.
globenewswire.com BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway…
benzinga.com BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(705.20) per share which missed the analyst consensus estimate of $(0.57) by 123619.3 percent. This is a 24.49 percent decrease over…
globenewswire.com BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of…
defenseworld.net BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives $24.80 Average PT from Brokerages Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) have earned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm,…
seekingalpha.com BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage, supported by three promising KRAS/RAS-targeted drug candidates. BBOT's lead asset, BB-8520, showed a 65%…
benzinga.com Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-expected earnings. Other big gainers: PRME, BZH, WULF, VRXA, BABA, ACDC, KC, PARR, SWMR, BBOT, KEX- benzinga.com JP Morgan Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $27 JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Overweight rating and announces Price Target of $27.
benzinga.com Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22 Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $22.
benzinga.com BridgeBio Oncology Q1 EPS $(526.11) Down From (54.230) YoY, BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(526.11).This is a 870.15 percent decrease over losses of $(54.23) per share from the same period last year.
globenewswire.com BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway…
globenewswire.com BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway…
benzinga.com This Arxis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. For full rating changes, check analyst ratings page. ARXS: Buy, $53 PT. See analyst views.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
247wallst.com Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a…- benzinga.com Canaccord Genuity Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23 Canaccord Genuity analyst John Newman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.
- benzinga.com BridgeBio Oncology Therapeutics Presents New Preclinical Data For BBO-11818 Inhibitor At American Association For Cancer Research Annual Meeting 2026 BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today presented new preclinical data for BBO-11818, a…
globenewswire.com BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines- benzinga.com BridgeBio Oncology Therapeutics Appoints Pedro J. Beltran CEO, Idan Elmelech COO, Effective April 25; Neil Kumar Appointed Executive Chairman BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the appointment of Pedro J. Beltran,…
globenewswire.com BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development…- benzinga.com BridgeBio Oncology Therapeutics Reveals Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models At The AACR Annual Meeting 2026; BBO-10203 Physically And Allosterically Disrupts The Interaction Between RAS And PI3Kα, Leading To Signaling Inhibition Without Inhibiting The Kinase Activity of PI3Kα And With No Observed Hyperglycemia BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today presented new preclinical data in an oral…
globenewswire.com BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed…
seekingalpha.com BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution BridgeBio Oncology Therapeutics is advancing differentiated KRAS inhibitors, targeting both active and inactive KRAS conformations in solid tumors, notably pancreatic cancer. BridgeBio Oncology's…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com FDA Grants BridgeBio Oncology Therapeutics Fast Track Designation To BBO-11818 BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumorsUpdated Phase 1 clinical data are expected…
globenewswire.com BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors
globenewswire.com BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway…- benzinga.com BridgeBio Announces Publication Of Preclinical Data Describing Discovery Of BBO-11818, panKRAS Inhibitor Targeting KRAS In ON And OFF States For Patients With KRAS Mutant Cancers BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS…
- benzinga.com HC Wainwright & Co. Maintains Buy on BridgeBio Oncology, Raises Price Target to $29 HC Wainwright & Co. analyst Robert Burns maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and raises the price target from $27 to $29.
- benzinga.com BridgeBio Oncology Q4 EPS $(0.49) Beats $(0.56) Estimate BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.56) by 13.12 percent.
benzinga.com This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - benzinga.com Stifel Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23 Stifel analyst Laura Prendergast initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.